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ABSTRACT
Rett syndrome (RTT) is a rare neurodevelopmental disorder that primarily affects 
females. In 99% of cases, RTT is believed to occur sporadically, or de novo.  However, in 
rare cases, RTT can be passed down from parent to child through gonadal mosaicism or 
asymptomatic carrier mothers.  It is known that having a child with an inherited genetic 
condition can lead to changes in family planning; however, little research has 
investigated this phenomenon in sporadic genetic conditions, such as RTT. This present 
study used a questionnaire to assess family planning decisions of parents of children with 
RTT. Forty-three percent of respondents reported that their family planning changed. The 
primary reason for reproductive stoppage was due to caregiver strain, and of those that 
chose reproductive continuation, the primary change was in the age gaps between their 
children. Parents were also asked to explain what they were told by healthcare providers 
about the recurrence of RTT and if they received genetic counseling. Seventy-eight 
percent reported they were told there was a 1% or less chance of recurrence of RTT and 
34% received genetic counseling. There was no significant association between those 
who received genetic counseling and those who altered their family planning decisions.  
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A Brief History of Rett Syndrome 
Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder that occurs 
in about 1 in 10,000 females and very rarely affects males (Laurvick et al., 2006). 
Individuals with RTT develop normally for a period between 6-18 months, followed by a 
period of regression. Affected individuals lose purposeful speech, hand use, and 
ambulation; they may also develop microcephaly and/or seizures. RTT was originally 
described by Dr. Andreas Rett, an Austrian neurodevelopmental pediatrician, in the 
1960s (Rett, 1966). Rett’s papers, written in German, were not well-known among 
European physicians at the time. Swedish pediatric neurologist Dr. Bengt Hagberg noted 
girls with similar features around the same time yet was unaware of the findings of 
Andreas Rett. It was not until 1983 that Rett syndrome was featured in an English 
publication by Hagberg and colleagues in Annals of Neurology (Hagberg et al., 1983). 
This paper described 35 female patients across France, Portugal, and Sweden all with 
similar features, including developmental regression, severe dementia with acquired 
microcephaly, loss of purposeful hand movements, autistic behaviors, and truncal and 
gait ataxia. Hagberg et al. (1983) concluded that these features were so striking that there 
was likely an underlying etiology that had not been previously described. Laboratory 
tests were inconclusive, and an exclusively female patient population raised suspicion of 
an X-linked dominant form of inheritance with lethality in males, but with little evidence 
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to support this claim. In addition, only one familial case out of the patients described in 
this paper was reported; two half-sisters born to the same unaffected mother with an 
unaffected half-brother from a third father (Hagberg et al., 1983). Thus, the inheritance 
pattern of Rett syndrome became a challenge to pinpoint. 
Genetics 
In 1999, Amir et al. were the first to report that mutations in the MECP2 (methyl-CpG-
binding protein 2, OMIM # 300005) gene, located at Xq28, caused RTT. Mutations were 
identified in the coding regions of MECP2 in 5 of 21 sporadic cases, as well as one 
familial case-a set of half-sisters that share the same mother (Amir et al., 1999). 
A larger study in 2008 investigated genotype-phenotype correlations in a cross-
sectional study of 245 females with RTT. Of note, 97% of affected girls and women in 
this study had a MECP2 mutation (Neul et al., 2008). By this time, over 200 mutations 
had been identified; however, 8 mutations accounted for 60% of cases according to data 
from RettBASE (Christodoulou et al., 2003). While genotype-phenotype correlations 
have yet to be fully described, Neul et al. (2008) determined that specific mutations 
impact clinical severity. Importantly, it was observed that certain mutations are 
associated with increased phenotypic severity in specific categories: ambulation, hand 
use, and language (Neul et al., 2008). 
Natural History 
Individuals with RTT develop typically between the ages of 6-18 months, followed by a 
period of regression (Amir et al., 1999). RTT is divided into typical (classic) and atypical 
(variant) forms. In 2010, a revision of the 2002 diagnostic criteria (Hagberg et al., 2002) 
was published to streamline clinical diagnosis, add required criteria, and distinguish 
variant forms of RTT. These criteria are continually being evaluated and will be updated 
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appropriately as more data becomes available to clinicians and researchers. Currently, the 
main criteria for RTT are: partial or complete loss of acquired purposeful hand skills, 
partial or complete loss of acquired spoken language, gait abnormalities, and stereotypic 
hand movements. All main criteria are required for a diagnosis of typical RTT, and two 
of these are required for a diagnosis of atypical RTT. In addition, supportive criteria 
include breathing disturbances when awake, bruxism when awake, impaired sleep 
pattern, abnormal muscle tone, peripheral vasomotor disturbances, scoliosis/kyphosis, 
growth retardation, small cold hands and feet, inappropriate laughter/screaming spells, 
diminished response to pain, and intense eye communication (Neul et al., 2010).  
Due to the wide phenotypic spectrum, variant forms of Rett syndrome have been 
described and named for their phenotype; for example, the “preserved speech variant,” 
also known as the Zapella variant, is considered the mildest RTT phenotype and is the 
most common atypical variant. A 2009 study identified 28 out of 29 females with Zapella 
variant RTT as having a missense or late-truncating MECP2 mutation. Even still, the 
patients with this variant exhibited variable phenotypes (Reniere et al., 2009). A second 
variant called the “early seizure variant,” or the Hanefield variant, is characterized by 
early-onset seizures (typically before developmental regression). MECP2 mutations are 
less common in this variant, and mutations in the CDKL5 gene (also located on the X 
chromosome) are more likely (Archer et al., 2006). The third variant is called the 
“congenital variant,” or the Rolando variant, and affected individuals present with 
abnormal development from birth. It has been shown that mutations in the FOXG1 gene 
(located on chromosome 14) may be more likely to cause the congenital form of RTT 
(Ariani et al., 2008). However, CDKL5 and FOXG1-associated conditions are now 
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recognized as distinct diagnoses from RTT and are no longer included in current studies 
of RTT.  
MECP2 mutations are also known to be responsible for a phenotypic spectrum 
outside of what is typically expected in RTT. In 1999, Wan et al. described a familial 
case in which a woman was found to have a mild learning disability and some motor 
problems. This woman had a sister and daughter both with classic RTT, as well as a son 
who was hemizygous for the mutation and passed away at one year of age due to neonatal 
encephalopathy (Wan et al., 1999). 
While phenotypically variable, RTT typically presents in a severe form and leads 
to lifelong disability. The quality of life of individuals with RTT has dramatically 
changed in recent years due to advanced therapies and interventions. Survival for classic 
and atypical RTT is greater than 70% at 45 years, and survival into the 5th decade has 
become typical (Tarquinio et al., 2015). According to Tarquinio et al. (2015), “presumed 
cardiorespiratory complications” are the leading cause of death in females with classic 
RTT according to data from the US RTT Natural History Study. With strong physician 
monitoring of nutrition, gastrointestinal issues, scoliosis, aspiration risk, and epilepsy, the 
lifespan of individuals with RTT may continue to increase as these risk factors are 
managed.  
Inheritance 
RTT is considered de novo, or “random,” in approximately 99% of cases. Few familial 
cases have been reported and are likely due to gonadal mosaicism in either the paternal or 
maternal germline, or to highly skewed X- chromosome inactivation (XCI) patterns in 
carrier mothers (Zhang et al., 2012). Zhang et al. (2012) found mutation type varied 
between paternally and maternally derived mutations in a cohort of Chinese patients. It 
5 
was found that point mutations are more likely to be of paternal origin, while single 
nucleotide gains/losses are more likely to be of maternal origin. Additionally, it was 
found that most familial cases were due to maternally derived mutations, due to either 
gonadal mosaicism or carrier mothers with highly skewed X-inactivation. These 
mechanisms are discussed in the succeeding paragraphs.  
Gonadal mosaicism refers to the presence of more than one distinct cell line in the 
germ cells (egg or sperm). Gonadal mosaicism may occur in one of two ways. In some 
cases, a mutation occurs in a germ cell which then continues to divide and creates a 
unique cell line. In other cases, a mutation can occur in a very early somatic cell, which 
then separates into somatic and germ cells, leading to both somatic and gonadal 
mosaicism. Mosaic individuals may exhibit mild symptoms of the condition or be 
completely asymptomatic (Zlotogora, 1998). 
X-inactivation refers to the silencing of either the maternal or paternal X- 
chromosome in female cells. The selection of the silenced chromosome is often random 
and varies from cell to cell; one cell population expresses the maternal X chromosome, 
while the remainder of the cells express the paternal X chromosome. This is referred to as 
the “X-inactivation pattern” and can vary from female to female; some may express a 
50:50 ratio, while others may express a more highly skewed ratio, such as 90:10 or 80:20 
(Plenge et al., 2002). It has been proposed that unaffected mothers of children with an X-
linked intellectual disability (XLID) syndrome, such as Rett syndrome, may have a 
highly skewed X-inactivation pattern. Plenge et al. (2002) suggest that skewed XCI 
patterns are more common in mothers of children with XLID syndromes due to selection 
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against the X-chromosome containing the mutation, leading to higher XCI patterns 
(≥80:20).  
Zhang et al. (2012) suggests that there are important clinical implications for 
mutation interpretation. For example, when insertion/deletion is observed in a patient, 
this is more likely due to a maternally derived mutation. In this case, the mother has a 
higher chance of being a carrier of the mutation or having germline mosaicism, and the 
family may be counseled on a modified recurrence estimate from the typical 1%. In the 
case of an affected child born to apparently healthy parents, the chance of recurrence can 
be as high as 50% if one parent is mosaic (Wilbe et al., 2017). However, there are 
currently no accepted methods in practice for analysis of sperm or eggs for germline 
mosaicism.  
Approximately 99% of cases of females with RTT are de novo and have been 
identified as almost exclusively arising from mutations on the paternal X chromosome 
(Trappe et al., 2001; Zhang et al., 2012). This is a likely explanation for the high female: 
male ratio of individuals with RTT. It was previously thought that RTT was male lethal; 
however, males with MECP2-related conditions have been reported and may have 
inherited the mutation either through a maternal de novo mutation or through carrier 
mothers (Trappe et al., 2001). Additionally, after determining that de novo MECP2 
mutations were primarily paternally derived, Trappe et al. (2001) concluded that these 
mutations were not in fact male lethal, and the paucity of affected males could be 
attributed to the fact that boys do not receive an X chromosome from their fathers. 
Venȃncio et al. (2007) describe a case report of a young female with classic RTT found 
to have a mutation in MECP2. The same mutation was found in her younger brother who 
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presented with severe growth and developmental delays early in life. He was found to 
have severe neurological abnormalities and died at 21 months of age due to 
complications from infection. However, the mutation was not present in blood from 
either parent, thus suggesting a case of maternal germline mosaicism (Venȃcio et al., 
2007). Typically affected males present with a severe phenotype, as all cells will express 
the mutated copy of MECP2. Four boys with progressive encephalopathy were described 
by Kankirawatana et al. (2006) All four patients had de novo mutations in MECP2. 
Symptoms included failure to thrive, respiratory insufficiency, microcephaly, and 
abnormal movements (Kankirawatana et al., 2006). This suggests that MECP2 analysis 
should be considered in males with these presenting features and speaks to the wide 
phenotypic spectrum of Rett syndrome, especially in males.  
Family Planning in The Presence of Genetic Conditions 
In this present study, family planning refers to decisions related to reproduction. 
Reproductive stoppage, or the decision to discontinue having children after a diagnosis is 
made, is a known phenomenon among families with a child diagnosed with autism 
(Wood et al., 2014; Hoffmann et al., 2014). Autism, like RTT, is not often diagnosed 
until the affected child is a few years old. Reproductive decisions may change after this 
diagnosis is made; Hoffmann et al. (2014) found that the first few years after a child’s 
diagnosis of autism, parents had subsequent children at a rate similar to controls. 
However, birth rates changed in the following years, and it was found that families had 
another child at a lower rate than controls (Hoffmann et al., 2014). This idea has yet to be 
studied in the RTT community. We hypothesize that families of children with RTT may 
make similar decisions, given that the diagnosis of RTT is often not made until early 
childhood after the child regresses. In addition, it is imperative to better understand the 
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factors that may contribute to these reproductive decisions, such as caregiver strain, 
interpretation of recurrence risk, and psychosocial aspects such as fear, guilt, and shame.  
Upon receiving a diagnosis of Rett syndrome, caregivers and family members 
must learn to manage not only their child’s health, but their own health as well. It is well 
understood that in general, parents of children with disabilities experience more adverse 
mental and physical health outcomes (Yamaoka et al., 2015). Laurvick et al. (2006) 
investigated this claim specifically in mothers of children with RTT. It was found that 
maternal physical and mental health is lower than the general population. Child behavior, 
caregiver demands, and family function were identified as the major predictors of 
maternal physical and mental health outcomes (Laurvick et al., 2006). Mothers of 
children with RTT are also at risk for adverse mental health outcomes such as severe 
depression (Sarajlija, Djuri, & Tepavcevi, 2013), and are also reported to have poorer 
mental health than physical health (Killian Jr. et al., 2016).  
Other non-genetic factors may play a role in a family’s decision to have more 
children after an RTT diagnosis. Because women with Rett syndrome now may live into 
middle age and beyond (Kirby et al., 2010), caregivers are responsible for ensuring their 
child receives lifelong care. This may be through dedicating themselves to the care of 
their child, but the question remains who will care for the child should he or she outlive 
the parents. Some parents may assume the siblings of their affected child will take charge 
of the care. There is currently no available research analyzing associations between 
caring for a child with RTT and the decision to have more children after the diagnosis is 
made. The strain on parents who are also caregivers coupled with the uncertainty of who 
will care for the child should they become unable and the uncertainty of having another 
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child with RTT are among many factors that may influence reproductive decisions.  
Being aware of these factors may provide the healthcare professionals caring for these 
families with increased knowledge of the impact a RTT diagnosis has on a family. By 
having a working knowledge of the possible questions and uncertainties parents of 
children with RTT face, healthcare professionals may be able to address them more 
accurately to provide more personal care for these families.  
The quality of life measures for caretakers of individuals with RTT are similar to 
those who are caring for individuals with other neurodevelopmental disorders. 
Difficulties with common features of RTT such as poor feeding and ambulation may 
have an impact on the physical and mental health of the caregiver (Killian Jr. et al., 
2016). RTT leads to a lifetime of disability, and caregiver demands can be great. 
Caregiver strain due to poor mental and physical health may certainly play a role in 
family planning; however, parents of children with RTT may not experience the same 
level of stress in caring for their children in early childhood as they may later in 
childhood and adulthood. It is not clearly understood if parents are making decisions 
based on their perceived future caregiving responsibilities, versus their current 
responsibilities when their child receives a diagnosis.  
In many cases, the specialist making a RTT diagnosis is a neurologist, 
developmental pediatrician, or a geneticist (Tarquinio et al., 2015). It is currently unclear 
to what extent these families are receiving genetic counseling, if at all. It is also not clear 
whether families are receiving the most accurate and up-to-date information on the 
genetics of RTT. It is not yet known if recurrence risk, typically quoted at 1% except in 
cases of gonadal mosaicism or carrier mothers, is a major factor in these parents’ 
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decision-making processes when it comes to future pregnancies. This present study aims 
to assess if families are receiving genetic counseling and by whom, as well as to 
determine what information they were given at the time of diagnoses that may have had 
an impact on family planning decisions.  
Parents of children diagnosed with RTT face a unique challenge when it comes to 
chance of recurrence. While the majority of cases are de novo, mothers may be 
unrecognized carriers of a MECP2 mutation due to skewed X-inactivation, and both 
maternal and paternal gonadal mosaicism are virtually impossible to rule out. This 
uncertainty may add a layer of complexity to families faced with making decisions about 
future pregnancies. The following quote is from the parent of a child with RTT regarding 
the diagnostic odyssey her family faced. (Knott, Leonard, & Downs, 2011):  
“Not long after diagnosis, I had a test to confirm that I was not a silent carrier of 
the mutation and when given the all clear, my husband and I decided to have 
another child. We had read that the chances of having a second child with RTT 
was miniscule, however, the concern was always present. (p.11)” 
The author went on to have a healthy daughter without RTT after her first daughter was 
diagnosed with RTT, yet she does not specify that she received any kind of family or 
genetic counseling on the matter to reach that decision. Parents of newly diagnosed 
children have many questions, one of them being “How will this affect planning for 
future children?” (Downs & Leonard, 2016). Currently, there is little literature on family 
planning decisions after a diagnosis of a typically de novo condition is made.  
There is, however, an abundance of literature regarding family planning decisions 
following a diagnosis of a condition in which the inheritance pattern is well-established. 
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Fragile X syndrome (OMIM #300624) is the most common cause of autism and 
intellectual disability in males (Hunter et al., 2014). Interviews of mothers with a known 
mutation in the gene FMR1, which incurs a 50% chance of passing on Fragile X 
syndrome to their children, revealed that 77% of women decided against having more 
children after learning their carrier status (Raspberry & Skinner, 2011). These women 
reported several factors that influenced their decision making, including reproductive 
risk, emotional/financial strain of another child with a disability, and the implication of 
“social judgments” should they choose to have more children knowing the risks involved.  
Another survey of individuals with a diagnosis of Peutz-Jeghers syndrome, an 
autosomal dominant cancer predisposition syndrome, revealed that 29% of respondents 
reported that their diagnosis influenced their family planning decisions, and 19% of these 
reported that they do not wish to have children at all (van Lier et al., 2012). These 
questions have yet to be explored in the RTT community. Although it is now known that 
RTT is not typically inherited from a parent as in Peutz-Jeghers syndrome, it was initially 
thought to be inherited from the mother prior to the discovery that MECP2 mutations 
were responsible. It is possible that healthcare professionals outside the field of genetics 
may not have the most up-to-date or accurate information on the recurrence risk of RTT.  
In this study, we aim to assess to what extent a RTT diagnosis affects family 
planning decisions. We aim to identify factors such as parental interpretation of 
recurrence risk, the accuracy of recurrence information provided at the time of diagnosis, 
and the extent to which genetic counseling was received by families. In addition, we will 
investigate the rates at which parents elected prenatal diagnosis of RTT as well as the 
uptake of parental genetic studies to determine carrier status for RTT.
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CHAPTER 2 
FAMILY PLANNING DECISIONS AFTER A CHILD’S DIAGNOSIS OF 
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Rett syndrome (RTT) is a rare neurodevelopmental genetic condition that affects about 
1/10,000 girls and very rarely affects males (Laurvick et al., 2006). It is an X-linked 
dominant condition caused by mutations in the MECP2 (methyl-CpG-binding protein 2, 
OMIM # 300005) gene, located at region Xq28 (Amir et al., 1999). RTT is characterized 
by a period of normal development between 6-18 months of age, followed by a period of 
regression. Though the clinical phenotype varies, the main diagnostic criteria for a 
diagnosis of RTT include partial or complete loss of acquired purposeful hand skills, 
partial or complete loss of acquired spoken language, gait abnormalities, and stereotypic 
hand movements (Neul et al., 2010). Other symptoms include seizures, vasomotor 
disturbances, scoliosis/kyphosis, and abnormal muscle tone.  
 RTT is considered sporadic in approximately 99% of cases. In the past, it was 
thought RTT was male lethal due to the paucity of affected males in the patient 
population. However, it was found that de novo cases typically arise due to mutations on 
the paternally inherited X chromosome (Trappe et al., 2001; Zhang et al., 2012). Few 
familial cases have been reported and are most likely maternally inherited. These cases 
are likely due to either parental gonadal mosaicism or carrier mothers with highly skewed 
X-inactivation (Zhang et al., 2012). While testing X-inactivation patterns in mothers is 
possible, it is nearly impossible to accurately screen either parent for gonadal mosaicism, 
making the assessment of recurrence risk a challenge.  
In the event of an apparently sporadic case, parents of a child diagnosed with RTT 
are often told that recurrence is unlikely (i.e., < 1%), however; parental perception of this 
risk estimate has not been well-studied. Additionally, it is not clear to what extent parents 
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are receiving genetic counseling, and if they are informed of the possibility of an 
increased recurrence risk due to undetected gonadal mosaicism or carrier mothers. These 
uncertain risk assessments may alter family planning decisions after a child’s diagnosis. 
In this present study, family planning refers to decisions related to reproduction. 
Reproductive stoppage, or the decision to discontinue having children after a diagnosis is 
made, is a known phenomenon among families with a child diagnosed with autism 
(Wood et al., 2014; Hoffmann et al., 2014). As in RTT, autism is often undiagnosed until 
the affected child is a few years old and symptomatic. The inheritance of autism is 
variable and multifactorial, and many parents never receive an explanation of the cause of 
autism in their child. Due to the limits of genetic testing, recurrence risk for autism is 
often difficult to explain and interpret for families. Parents of children with autism may 
experience a similar type of uncertainty as parents of children with RTT. One study 
reported that, in the first few years after a child’s diagnosis of autism, parents had 
subsequent children at a rate similar to controls. However, birth rates changed in the 
following years, and it was found that families had another child at a lower rate than 
controls (Hoffmann et al., 2014). This idea has yet to be studied in the RTT community. 
We hypothesize that families of children with RTT may make similar decisions, given 
that the diagnosis of RTT is often not made until early childhood after the child regresses 
and there is a similar level of uncertainty involved. 
Reproductive decision-making in the wake of a genetic syndrome with an 
established inheritance pattern has been well-studied. While RTT is the leading cause of 
intellectual disability in females, Fragile X syndrome is the leading cause of autism and 
intellectual disability in males. Fragile X syndrome is caused by a trinucleotide repeat 
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expansion in the FMR1 gene, also located on the X chromosome. Typically, mothers are 
carriers of an expansion, and have a 50% chance to pass on the full expansion to their 
sons in an X-linked recessive pattern. A study of known Fragile X carriers revealed that 
77% of women decided against having more children after learning their carrier status 
(Raspberry & Skinner, 2011). While the inheritance pattern of Fragile X syndrome and 
RTT differ, there is phenotypic overlap between the two syndromes. Women in this study 
reported several factors that influenced their reproductive decision making, including 
reproductive risk, emotional/financial strain of another child with a disability, and the 
implication of “social judgments” should they choose to have more children knowing the 
risks involved. This present study aims to identify factors in this same decision- making 
process for both mothers and fathers of children with RTT. 
RTT is a condition characterized by severe lifelong disability. As described by 
mothers in the above-mentioned study, there is both emotional and financial strain in 
caring for one child with a disability, let alone multiple children with disabilities. The 
mental and physical health of parent caregivers of children with special needs have been 
well-studied. In general, parents of children with disabilities experience increased adverse 
mental and physical health outcomes (Yamaoka et al., 2015). Specifically, mothers of 
children with RTT are known to have poorer mental and physical health than the general 
population (Laurvick et al., 2006) and are at an increased risk for depression (Sarajlija, 
Djuri, & Tepavcevi, 2013). Caregiver strain, along with uncertainty surrounding 
recurrence risk, must be considered when assessing a family’s desire to alter their family 
planning strategy. It is hypothesized that a combination of genetic and non-genetic 
factors ultimately influences parental family planning decisions and strategies. Families 
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must navigate complex genetic information, manage the ongoing medical needs of their 
child with RTT, and deal with parenthood and the emotional distress that comes 
regardless of a genetic diagnosis. In addition, parents may experience feelings of guilt, 
shame, and fear, and may have little guidance in managing this distress. This present 
study aims to assess to what extent a RTT diagnosis affects family planning decisions, 
the accuracy of information given to parents at the time of diagnosis, and the measures 
parents have taken to manage these risks such as prenatal diagnosis of RTT and parental 
genetic studies.  
MATERIALS AND METHODS 
Participants 
Approval for this study was obtained from the University of South Carolina Institutional 
Review Board. Biological parents of individuals of any age with a clinical and/or genetic 
diagnosis of RTT were eligible to participate in this study. Parents of children with 
known MECP2 duplications, FOXG1 alterations, or CDKL5 variants were excluded from 
this study. Less information is widely available on these conditions, and although they 
are associated with RTT, they do not carry the same implications as a diagnosis of Rett 
syndrome presumed or known to be to be associated with a MECP2 alteration. An 
invitation was sent to members of RettNet, a community for the family members of 
individuals with RTT, through an email listserv. The invitation was sent once a month for 
three months (October 2017-January 2018). In addition, an invitation to participate was 
posted on the public Facebook page RettSyndrome.org once a month for three months. 
There were 323 individuals that completed at least part of the online survey. Of these, 
304 completed at least 80% of the survey and met the inclusion criteria. 
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Questionnaire Design 
We developed an online questionnaire using SurveyMonkey. The questionnaire had four 
major sections. The first section included information on the diagnosis of the individual 
with RTT (age, age at diagnosis, diagnosis delivery, genetic status). The second section 
included questions related to subsequent pregnancies after their child was diagnosed with 
RTT (number of pregnancies, type of genetic screening/testing during pregnancy, genetic 
diagnosis for RTT). Participants were prompted to answer the same set of questions for 
up to 4 subsequent pregnancies. The first two sections consisted of primarily multiple-
choice questions with few free-response questions. The third section included several in-
depth free response questions (how their child’s diagnosis impacted their family 
planning, what information they received about recurrence risk). The final section 
included participant demographics. The questionnaire was pilot tested by a staff member 
of RettSyndrome.org, who is also the mother of a daughter with RTT. The questionnaire 
took approximately ten minutes to complete.  
Analysis 
Descriptive statistics were used to describe quantitative questionnaire data. Chi-square 
analysis was used to analyze relationships between genetic counseling and family 




2.1 Demographics. A total of 323 participants completed all or part of the survey. Only 
biological mothers and fathers of children with RTT were eligible to participate in this 
study. Those that reported they were not biological parents and those that did not 
complete greater than 80% of the survey were excluded from analysis, resulting in a total 
of 304 responses. Participants could skip any question they did not want to answer; thus, 
there are variations in the number of responses per question analyzed. Of the participants 
that met inclusion criteria, 89.5% (272/304) were mothers and 10.5% (32/304) were 
fathers. Participants were primarily Caucasian, college-educated, and married. 
Demographics are outlined in Table 2.1.  
2.2. Family Planning Decisions. Forty-three percent of participants (117/272) responded 
that having a child with RTT changed their family planning decisions, 50.4% (137/272) 
responded that it did not, and 6.6% (18/272) were unsure (Figure 2.1). Several major 
themes emerged when analyzing how a diagnosis of RTT impacted family planning. 
Detailed responses were provided by 194 participants regarding how their family 
planning decisions were or were not altered. Three major themes emerged: parental 
decisions to stop reproduction, parental decisions to continue reproduction, and parental 
decisions to make no changes to their reproductive plans based on their child’s RTT 
diagnosis. Subthemes are presented in Figures 2.2-2.4. Analysis of these themes and their 
subthemes, as well as examples of participant responses, are outlined in Table 2.2. 
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2.2a. Decision to stop reproduction. There were 70 responses indicating that parents 
decided to stop having children after their child’s diagnosis of RTT. Subthemes in this 
category include stoppage due to caregiver strain (38/70), the decision to dedicate their 
care to the affected child/did not wish to have more children (14/70), and fear/uncertainty 
of having another child with RTT or other special needs (18/70).  
2.2b. Decision to continue reproduction. There were 37 responses indicating that parents 
decided to continue having children after their child’s diagnosis of RTT. Subthemes in 
this category include continuation for the reason of having a sibling either for their child 
with RTT or for a typical child (12/37), continuation because the interpretation of the risk 
for future affected children was low (8/37), and a decision to have more children but with 
different age gaps between children than previously planned (17/37). 
2.2c. No change in family planning decisions. There were 82 responses indicating that a 
diagnosis of RTT did not alter family planning decisions. One group of participants 
indicated that they were already done having children by the time their child was 
diagnosed (34/82). Ten participants were already pregnant at the time of the diagnosis, 16 
participants responded that they were still planning to have the same number of children 
regardless of the diagnosis, 7 participants reported having either a tubal ligation or 
vasectomy prior to becoming aware of their child’s diagnosis, and 5 participants were 
mothers who responded that their age was the major factor in stoppage. A group of 11 
participants had miscellaneous reasons to stop reproduction that did not fit into categories 
including inability to get pregnant or did not give specific reasons.  
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2.2d. Undecided. A group of five participants reported that they were still unsure if their 
family planning decisions would change. Reasons include parental disagreement (2/5) 
and difficulty coming to a decision due to a variety of factors (3/5). 
2.3 Future Pregnancies. Participants were asked questions regarding subsequent 
pregnancies after their child was diagnosed; 46.7% (136/291) reported that they had at 
least one subsequent pregnancy and 53.3% (155/291) reported that they had no 
subsequent pregnancies. Prenatal diagnostic testing via amniocentesis or chorionic villus 
sampling (CVS) for RTT was performed on 27 pregnancies, and prenatal diagnostic 
testing for other conditions such as chromosome abnormalities was performed for 37 
pregnancies. Of note, none of the reported pregnancies tested for RTT prenatally were 
affected.  
2.4. Recurrence Risk Information. Participants were asked questions regarding 
reproductive information they received prior to having future children; 55.5% (146/263) 
report that they were told their chances of having future children with RTT, 39.2% 
(103/263) reported they were not told their chances, and 5.3% (14/263) were unsure. Of 
the 263 that answered this question, 183 gave detailed responses regarding the 
information they received. Thematic analysis revealed five different categories of 
information participants received (Figure 2.5). Many respondents (78.7%, 144/183) 
reported that they were told their chances of having another affected child were 1% or 
less, or unlikely. Of note, 11 of these responses specifically mentioned being counseled 
on gonadal mosaicism (both maternal and paternal) and the possibility of carrier mothers. 
The second most common response (11.4%, 21/183) was by parents that were not told 
anything or did not have this discussion with their providers. A small subset (3.3%, 
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6/183) reported that this information was not known at the time of their child’s diagnosis, 
and another small subset (3.3%, 6/183) were told a higher number, such as 5%, 25%, or 
50% or more. Of note, one of these responses indicated that the mother was found to be 
an asymptomatic carrier for RTT; therefore, she was correctly informed her chance of 
having an affected child is 50%.  Further, 3.3% (6/183) were told the chance was zero or 
impossible.  
2.4a. Parental Genetic Testing. Participants were asked if either parent had received 
genetic testing to determine their carrier status for MECP2 mutations. There were 272 
responses to this question; 16.5% (45/272) report the mother only had genetic testing, 
1.5% (4/272) report the father only had genetic testing, 22.8% (62/272) report both 
parents had testing, 58.5% (159/272) report neither had testing, and 0.7% (2/272) were 
unsure. Of the mothers that received testing, two were found to be asymptomatic carriers. 
There were no reports of carrier fathers.  
2.5. Genetic Counseling. Participants were asked whether they had received genetic 
counseling. There were 272 responses to this question; 34.6% (94/272) reported they had 
received genetic counseling. Of those that chose to disclose who provided the genetic 
counseling, 82% (82/100) reported they were counseled by a genetic counselor, and 18% 
(18/100) were counseled by another physician or provider. Sixty-one percent of 
respondents (166/272) reported they did not receive genetic counseling, and 4.4% 
(12/272) were unsure. There was no significant association between families receiving 





The themes identified in this present study allude to previous findings in the literature 
regarding family planning. As expected, there were more participants that made decisions 
to stop reproduction based on non-genetic factors (i.e., caregiver strain), versus stopping 
based on the recurrence risk of RTT. While only about half of participants reported being 
informed of their chances to have another affected child, participants more frequently 
reported that they stopped reproduction based on recurrence risk than continued despite 
recurrence risk. Families are often quoted a “1% or less” recurrence risk (except in 
situations of gonadal mosaicism or carrier mothers) when discussing the chances for their 
future children to have RTT. This study was the first to investigate how parents of 
children with RTT interpreted this chance and applied it to their family planning 
decisions.  
 Caregiver strain was the most commonly reported reason for reproductive 
stoppage. It is known that individuals with RTT have many complex medical issues, 
including seizures, feeding problems, mobility issues, and poor communication skills. 
Affected individuals require lifelong care and are surviving longer than they have been in 
the past; currently, survival into the fifth decade is common (Tarquinio et al., 2015). 
Parents must balance their care between their affected child and their other children; a 
commonly reported reason for reproductive stoppage included parents reporting wanting 
to dedicate all their time to their current children. For example, one participant 
responded, “After the diagnosis we choose to put all our efforts into giving our daughter 
the best possible life that we could.” The second most common reason for reproductive 
stoppage was due to fear or uncertainty of RTT happening again in a future child. Of 
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note, some participants made the distinction that it was not solely another child with RTT 
that was concerning but having another child with any kind of special needs, as the needs 
of their affected child were so great. It is uncertain if recurrence of RTT or recurrence of 
disability was more strongly associated with reproductive stoppage.  
 There is literature regarding reproductive stoppage in the presence of known 
heritable genetic conditions, such a Fragile X syndrome. Mothers who are carries for 
Fragile X syndrome have a 50% risk to have an affected son with each male pregnancy 
and a 50% chance to have a carrier daughter with each female pregnancy. Raspberry & 
Skinner et al. (2011) found fear of “social judgments” was a reason for reproductive 
stoppage by Fragile X carrier mothers. While many parents of children with RTT 
reported stopping due to the strain of having a child with a disability as well as fearing 
having another child with similar needs, no participants reported feeling social pressure 
or judgements when making family planning decisions. This could be due in part to the 
fact that many parents are likely informing family and friends that RTT happened in their 
child sporadically and there is a low chance for it to occur again; however, it is possible 
there is pressure to stop having children to dedicate themselves to caring for their child 
with special needs. Although stopping reproduction to dedicate more care to their 
affected child was a commonly reported reason for stopping reproduction, no participants 
reported that this was due to any kind of pressure from family, friends, or society.  
In terms of reproductive continuation, many participants reported wanting a 
sibling either for their child with RTT or for their typical child. A few reported wishing to 
have another child that could help with the care of their child with RTT as he/she aged 
and would require more care. Additionally, another set of participants wanted to have 
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another typical child so that the lone sibling of an affected individual would not face the 
burden of caring for him/her in adulthood alone. Adult siblings of individuals with 
intellectual disabilities are known to take on a variety of roles when their sibling reaches 
adulthood, including caregiver, friend, advocate, legal representative (such as a 
guardian), and informal service coordinator (Hall & Rosetti, 2017). This could be a 
possible motive behind parental desire for more typical children, but interpretations of 
those future sibling roles were not explicitly stated by any respondents.  
 When families receive a diagnosis of RTT, frequently from a neurologist, 
developmental pediatrician, or geneticist (Tarquinio et al., 2015), it is imperative they 
receive genetic counseling. Genetic counseling is defined as the “process of helping 
people understand and adapt to the medical, psychological and familial implications of 
genetic contributions to disease” (National Society of Genetic Counselors’ Definition 
Task Force, 2006). In the case of RTT, parents should receive counseling based on up-to-
date literature regarding the genetics of RTT, de novo vs. inherited RTT, recurrence risk 
in future pregnancies, and potential genetic testing in the event of a suspected carrier 
mother. Prior to this study, it was unclear to what extent parents of those with RTT were 
receiving genetic counseling. Typically, genetic counseling is provided by a genetic 
counselor. In areas where genetic counselors are not readily available, physicians or other 
practitioners may provide this counseling. In the event a diagnosis is made by a 
neurologist or developmental pediatrician, rather than a geneticist, there may be a delay 
in reception of genetic counseling due to wait times for genetics referrals, or the family 
may never receive genetic counseling at all. Less than half of respondents reported 
receiving genetic counseling. Of those, the majority did receive counseling from a genetic 
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counselor. It is possible, however, that participants received some degree of genetic 
counseling but may not have been aware of it at the time due to the misunderstanding that 
genetic counseling is only provided in a geneticist’s office, or only by a genetic 
counselor. Even discussing recurrence risk with a physician qualifies as some degree of 
genetic counseling. Therefore, reception of genetic counseling may be underreported in 
this patient population.  
 Participants were invited to explain what they were told in general regarding 
recurrence risk of RTT. Thematic analysis of these responses revealed that the majority 
were told that there was a less than 1% chance, “minimal,” or “negligible” chance that 
they would have another affected child. Of these responses, there were several 
participants that reported specific information on recurrence risk in the presence of 
gonadal mosaicism or carrier mothers. For example, one mother reported being told that 
“although I, [the] mother, did not have any abnormalities in my genetic makeup, my eggs 
may carry the genetic mutation.” Another participant discussed the changes to risk based 
on carrier status: “If I (the mother) carry [the mutation] our chances go up. But if not it’s 
like 1:100,000.” As stated previously, this information may have been shared by a genetic 
counselor or another provider. Further investigation into information received by parents 
from genetic counselors and information received from other practitioners is warranted. 
However, no significant difference was reported regarding family planning decisions 
between those that received genetic counseling and those that did not.  
 Other participants reported being told the chance for recurrence was “zero” or 
impossible. It is unclear whether these participants were truly told the risk was zero, or if 
that was their interpretation of a “1% of less” risk estimate. To some, zero and “1% or 
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less” may be equivalent. Patients interpret risk estimates in a variety of ways, and it is not 
clear whether the responses to this question were their own interpretation or were the 
words of the genetic counselor or other provider. Many participants report not discussing 
recurrence risk with a healthcare provider for a variety of reasons. Some chose not to 
speak with a genetic counselor because they were not planning to have any more 
children, while others reported simply not having this discussion at all. For others, the 
chance of recurrence was simply not known at the time of their child’s diagnosis, and 
they did not receive any information. A small subset of participants was told a risk 
number greater than 1%, such as 5%, 25%, or 50%. One respondent who was found to be 
an asymptomatic carrier of a MECP2 mutation reported that she was informed that there 
was a 50% chance if the future baby was a boy and an unknown chance if the future baby 
was a girl. It is possible that this participant was referring to the uncertainty of whether a 
daughter would have highly skewed X-inactivation, but this is not clear based on her 
response. In the presence of gonadal mosaicism, there can be a risk of up to 50% to have 
another affected child; it is complicated to counsel on this number, however, since it is 
virtually impossible to test eggs or sperm to determine the level of mosaicism. It is 
unclear whether those that reported being informed of a 50% risk were told this in the 
context of inheritance or of gonadal mosaicism.  
Further, one of the four participants that reported being told a 50% recurrence risk 
was found to be an asymptomatic carrier of a MECP2 mutation. This participant, a 
mother of a male child with RTT, has a twin sister with RTT. In this case, she had a 50% 
chance of passing on her X chromosome with the MECP2 mutation, and a 50% chance of 
passing on her X chromosome without the MECP2 mutation, regardless of the sex of the 
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baby. This mother had unique insight into family planning decisions when the mother is 
an asymptomatic carrier. She reported  
“…we got pregnant when [son with RTT] was around 1 year old. But we 
terminated the pregnancy because we did not know what was wrong with him and 
we did not know what to test for. We couldn't risk having another child with such 
high needs. We got pregnant again and then the insurance company finally agreed 
to let us do a full DNA test and found out that I am an asymptomatic carrier. 
Praise the heavens that this second pregnancy did not have Rett syndrome.” 
Her experience entails many different themes surrounding family planning, such as fear 
and uncertainty of having another affected child, potential caregiver strain from having a 
child with complex medical needs and pursuing parental genetic testing to determine 
parental carrier status to gain a better understanding of their personal recurrence risk.  
Limitations 
This study had several limitations that were potential barriers to data analysis. Most of 
the participants were educated Caucasian females. Having a more diverse pool of 
participants may have given more insight into how different groups of people may 
interpret recurrence risk, and how different groups deal with the strain of having a child 
with a disability. Religion was not asked as a demographic question, but it is possible 
religious and spiritual beliefs played a role in family planning.  
This questionnaire was only distributed electronically. It is possible more groups 
may have been reached with the use of a mailed paper survey, as many do not have 
access to Internet, email, or social media sites where the questionnaire was distributed.  
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Directions for Future Research 
There has been little research in the field of genetic counseling regarding counseling 
families on recurrence risk in the presence of a typically de novo condition, primarily 
surrounding the possibility of gonadal mosaicism. Further, the RTT community may 
benefit from analysis of current genetic counseling practices of genetic 
counselors/geneticists, developmental pediatricians, and neurologists to assess their way 
of reporting recurrence risk to parents. It is also unclear to what extent counseling on the 
prognosis of RTT has to do with decisions regarding family planning. This could give 
more insight into parent perceptions of the roles siblings of their children with RTT may 
take on as children and as adults.  
Conclusion 
This present study was a pilot study into the perceptions of parents of children with RTT 
of recurrence risk and how their family planning was impacted. It was found that more 
participants altered their family planning based on non-genetic factors, such as caregiver 
strain and desire for their children (both with RTT and without) to have siblings, rather 
than their perception of the recurrence risk. Non-genetic factors were reported more 
frequently by both groups of parents, those who stopped reproduction and those who 
continued. Genetic counseling had no significant association with altering family 
planning decisions. More research is needed to determine the extent families are 
receiving genetic counseling and whether that includes the chance for the possibility of 






Table 2.1 Demographics 
  Percentage Frequency 
Relationship to Individual 
with RTT 
Biological Mother 89.5 272 
Biological Father 10.5 32 
Total 100 304 
Race/Ethnicity 
Caucasian 84.5 229 
African-American 1.1 3 
Hispanic/Latino 5.9 16 
Native American 0.4 1 
Asian/Pacific Islander 0.7 2 
Multiethnic 3 8 
Prefer not to respond 1.1 3 
Other 3.3 9 
Total 100 271 
Education Level 
Less than high school 0.7 2 
High school diploma or 
equivalent 
5.9 16 
Some college 20.2 55 
Associate’s degree 13.2 36 
Bachelor’s degree 29 79 
Graduate degree 27.6 75 
Prefer not to respond 3.3 9 
Total 100 272 
Employment Status 
Employed 55 149 
Unemployed 1.1 3 
Stay-at-home parent 28.8 78 
Student 0.4 1 
Retired 5.9 16 
Other 8.9 24 
Total 100 271 
Marital Status 
Single 1.5 4 
Married 83.1 226 
Divorced/Separated 8.8 24 
In a relationship but not 
married 
6.6 18 




Table 2.2 Thematic Analysis of Family Planning Decisions Based on a Child’s Diagnosis 
of RTT 
 
Theme Subthemes Example(s) 
Affected Decision Making: 
Decided to have more 
children 
Addition of another sibling 
for their child with RTT 
and/or for their typical 
child 
“We wanted a sister for our 
Rett daughter.” 
 
“We wanted the typical 
child to have a typical 
sibling.” 
Delayed having more 
children/intentionally 
altered children’s age gaps 
from original plan 
“We delayed planning for a 
third child to adjust to our 
new life.” 
Interpreted recurrence risk 
as low 
“No, we were aware that 
Rett is caused by a random 
mutation and was unlikely 
to repeat.” 
Affected Decision Making: 
Decided to cease having 
children 
Caregiver strain 
“Rett syndrome consumes 
your entire life, not just 
severe complications with 
your child. Your marriage, 
relationships and you as 
the caretaker, your health.” 
 
“Not for fear of Rett but 
because of the amount of 
time and energy we would 
have to devote to our 
daughter.” 
Uncertainty or fear 
regarding recurrence/Fear 
of having another child 
with RTT or other special 
needs 
“I felt I couldn’t risk 
bringing another child into 
the world with Retts. I 
couldn’t do that to another 
child…” 
 
“I could not take the risk of 
another child potentially 
having any type of special 
needs.” 
Did Not Affect Decision 
Making 
Already pregnant when 
diagnosis received 
“We were nine months 
pregnant with daughter #4 





children/Had tubal ligation 
or vasectomy prior to 
diagnosis 
“I was 47 when [child] was 
diagnosed.” 
 
“My husband chose to 
have a vasectomy when 
our child with RTT was a 
newborn.” 
 
“I was finished having 
children when she got her 
diagnosis.” 
Planned to have more 
children regardless of 
diagnosis 
“We wanted a third child in 




“After my Rett daughter 
passed in 2015, I have 
considered another child. 
My husband does not 
agree.” 
Weighing Options 
“I haven't fully decided 
yet. I'd like to have another 
but I’m worried about 
coping and giving my 
daughter with Rett 
syndrome enough time and 
input. I want her to achieve 
All she can within the 
sphere of her abilities. I 
want to give my all to this. 
At the same time I'd like 
my older daughter to have 
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low
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My name is Erin Huggins and I am a graduate student in the Genetic Counseling Training 
Program at the University of South Carolina. I am conducting a research study as part of 
the requirements of my degree in Genetic Counseling, and I would like to invite you to 
participate.  
I am studying the impact a Rett syndrome diagnosis has on family planning. If you decide 
to participate, you will be asked to complete an electronic survey. In particular, you will 
be asked questions about your child’s diagnosis, decisions regarding genetic testing, and 
your pregnancy history. Participation is voluntary, and you will be able to skip any 
questions that you prefer not to answer. Those eligible to participate include biological 
parents of an individual with a clinical and/or genetic diagnosis of Rett syndrome. If a 
genetic diagnosis has been made, parents of individuals with a MECP2 alteration are 
eligible. Those not eligible to participate includes parents of individuals with genetic 
diagnosis of MECP2 duplication, FOXG1 alteration, or CDKL5 alteration.  
Survey responses are anonymous. Surveys will only be accessible by myself and the 
research team. So, please do not fill in your name, your child’s name, or other identifying 
information on the survey. The results of the study may be published or presented at 
professional meetings, but your identity will not be revealed. Taking part in this study is 
your decision. Completion of all or part of the survey implies you have given your 
 
45 
consent to participate. However, participation is not required, and you may exit the 
survey at any time or decide not to answer any question with no penalty.  
I will be happy to answer any questions you have about the study. You may contact me at 
rettsyndromestudy@gmail.com if you have study related questions or problems. If you 
have any questions about your rights as a research participant, you may contact the Office 
of Research Compliance at the University of South Carolina at 803-777-7095. 
Your time is greatly valued and appreciated. If you would like to participate, please 


















1. What is your relationship to the individual with Rett syndrome? 
o Biological mother 
o Biological father 
o Other (please specify) 
 
2. Has anyone else in your family been diagnosed with a neurodevelopmental disorder 









4. How old was your child when she/he received a clinical diagnosis of Rett syndrome 













o Developmental Pediatrician 
o Unsure 
o Other (please specify) 
 






7. If yes, at what age did your child receive a genetic diagnosis (from a laboratory test)? 
 




o Developmental Pediatrician 
o Unsure 








o No, she/he has a change in a different gene (please specify) 
 
10. During the pregnancy of your child who has Rett syndrome, was any prenatal genetic 
screening or testing performed? Select all that apply. 
 First trimester screen (Blood test and ultrasound performed between 10 and 13 
weeks gestation to screen for chromosomal conditions and some birth defects) 
 Second trimester/quad screen (Blood test performed between 15 and 22 weeks 
gestation to screen for chromosomal conditions and major physical defects such 
as spina bifida) 
 Non-Invasive Prenatal Screening (Blood test performed any time after 10 weeks 
gestation to screen for chromosomal conditions, including those involving sex 
chromosomes-not available prior to 2011) 
 Chorionic Villus Sampling (CVS) (Procedure in which a catheter is inserted 
through the mother's cervix to take a small sample of cells from the placenta) 
 Amniocentesis (Procedure in which a needle is inserted through the mother's 






11. What were the reasons for this screening/testing during pregnancy? Select all that 
apply. 
 Routine screening 
 Advanced Maternal Age 
 Suspected genetic condition 
 Prefer not to respond 
 Not applicable 
 Other (please specify) 
 
12. When your child was diagnosed with Rett syndrome, how many other children did 
you already have? 
o None 
o Number of children 
 
13. What ages were your other children at the time of your child’s diagnosis? Please list 
each child's age separated by a comma (ex. 5,7). 
 
14. Did you/the child's mother have any more pregnancies after your child was diagnosed 
with Rett syndrome? 
o Yes 
o No 




15. Please indicate the number of pregnancies you/the child's mother had after your child 
was diagnosed with Rett syndrome 
 
16. You will be prompted to answer these questions for up to four subsequent 
pregnancies. Only answer as many question sets as there were pregnancies after your 
child was diagnosed with Rett syndrome. 
Please answer the questions below for the first pregnancy after your child was diagnosed 
with Rett syndrome. 
o Was prenatal genetic screening for chromosome conditions, such as Down 
syndrome, performed via a blood draw on this pregnancy (Note: this is not the 














17. If yes, please select all that apply. 
 First trimester screen (Blood test and ultrasound performed between 10 and 13 
weeks gestation to screen for chromosomal conditions and some birth defects) 
 Second trimester/quad screen (Blood test performed between 15 and 22 weeks 
gestation to screen for chromosomal conditions and major physical defects such 
as spina bifida) 
 Non-Invasive Prenatal Screening (Blood test performed any time after 10 weeks 
gestation to screen for chromosomal conditions, including those involving sex 
chromosomes-not available prior to 2011) 
 Other (please specify) 
 
18. What were the reasons behind the decision to receive prenatal screening? Please 
select all that apply. 
 Routine screening 
 Advanced Maternal Age 
 Suspected genetic condition 








19. Was prenatal diagnostic testing for chromosome conditions, such as Down syndrome, 
performed for this pregnancy? 
o Yes: Amniocentesis 
o Yes: CVS 
o No 
o Unsure 
o Prefer not to respond 
 
20. If yes, what were the results of this test? 
 
 
21. Was prenatal diagnostic testing for Rett syndrome performed on this pregnancy (via 




22. If yes, what were the results of this test? 
 
23. What influenced the decision to receive (or not receive) prenatal diagnostic testing for 
Rett syndrome? Your answer may be as detailed as you wish. You are not required to 




24. Did you/the child's mother have more than one pregnancy after your child was 




(Questions 16-24 repeat for up to 4 subsequent pregnancies) 
 
51. Did your child's Rett syndrome diagnosis alter your family planning (i.e., the decision 





52. Please explain your response in as much detail as you wish. 
 
53. Did either biological parent of your child with Rett syndrome receive genetic testing? 
o Yes-biological mother received genetic testing 
o Yes-biological father received genetic testing 







54. If yes, what were the results of the test? 
Mother’s Genetic Test Results: 
Father’s Genetic Test Results: 
 





56. Please explain to the best of your knowledge how Rett syndrome is inherited. 
 














60. If so, by whom? 
o Certified genetic counselor 
o Other physician or provider (please specify) 
 












63. What is your current age? 
 
64. What was your age at the time your child with Rett syndrome was born? 
 









67. What is your race/ethnicity? Check all that apply. 
 Caucasian 
 African-American 
 Hispanic or Latino 
 Native American or American Indian 
 Asian/Pacific Islander 
 Prefer not to respond 
 Other (please specify) 
 
68. What is your highest degree of education? 
 Less than high school 
 High school diploma or equivalent 
 Some college 
 Associate’s degree 
 Bachelor’s degree 
 Graduate degree 





69. What is your employment status? 
o Employed 
o Unemployed 
o Stay-at-home parent 
o Student 
o Retired 
o Prefer not to respond 
o Other (please specify) 
 




o In a relationship but not married 
o Prefer not to respond 
